CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired HemaCare Corporation for $379.8 million in cash, a transaction completed in January 2020, structured as all cash.
HemaCare Corporation operates in Manufacturing Support — Biologics / cell therapy, is based in United States (Los Angeles, California). HemaCare Corporation was a business specializing in the production of human-derived cellular products for the cell therapy market.
The acquisition of HemaCare expands our comprehensive portfolio of early-stage research and manufacturing support solutions to encompass the production and customization of high-quality, human-derived cellular products to better support clients' cell therapy programs. The purchase price of HemaCare was $379.8 million in cash.
Manufacturing Support segment, cell therapy
The acquisition of HemaCare expands our comprehensive portfolio of early-stage research and manufacturing support solutions to encompass the production and customization of high-quality, human-derived cellular products to better support clients' cell therapy programs. The purchase price of HemaCare was $379.8 million in cash.Charles River FY2020 10-K, Business Acquisitions note
Advisory firms were not disclosed for this transaction.